Loading…
PHIO
Phio Pharmaceuticals Corp.
NASDAQ· Healthcare· Biotechnology· CUSIP 71880W501
$1.13+0.89%Price as of Aug 29, 18:43 UTC · updated once a day, after the close
Key metrics
- Market cap
- $13.13M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.0x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.29
- ROE
- -113.71%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.79
- 52-week high
- $4.19
- 52-week low
- $0.81
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.4% over 5Y.
today you would have $4.61▼ -99.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 14 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.05 | $1.80 | $6.84 | $40.18 | $108.00 | $290.52 | $1,015.74 | $1,960.20 | $33,026.40 | $42,471.00 | $226,908.00 | $950,400.00 | $1,722,600.00 | $1,336,500.00 | |
| P/S | 734.1x | — | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| KALAKALA BIO, Inc. | $0.69 | — | 1.5x | — | -345.32% | $13.35M |
| GTBPGT Biopharma, Inc. | $0.30 | 0.1x | 3.8x | — | -113.52% | $13.53M |
| MBRXMoleculin Biotech, Inc. | $0.65 | 0.0x | 0.4x | — | -1371.64% | $12.66M |
| ICUSeaStar Medical Holding Corp | $3.09 |
About the company
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
- 6
- King of Prussia, United States
Company description provided by Yahoo Finance.